25 results
424B4
PRFX
PainReform Ltd
17 Apr 24
Prospectus supplement with pricing info
4:14pm
.
Certain distributions treated as dividends that are received by an individual U.S. Holder from a “qualified foreign corporation” may be classified … as a PFIC for the 2023 taxable year until after the close of the year, and there can be no assurance that we will not be classified as a PFIC in any
F-1/A
PRFX
PainReform Ltd
15 Apr 24
Registration statement (foreign) (amended)
9:41am
as dividends that are received by an individual U.S. Holder from a “qualified foreign corporation” may be classified as “qualified dividend income,” — which … year until after the close of the year, and there can be no assurance that we will not be classified as a PFIC in any future year.
Default PFIC Rules
F-1
PRFX
PainReform Ltd
1 Mar 24
Registration statement (foreign)
4:34pm
.
Certain distributions treated as dividends that are received by an individual U.S. Holder from a “qualified foreign corporation” may be classified … will be characterized as a PFIC for the 2023 taxable year until after the close of the year, and there can be no assurance that we will not be classified as a PFIC
6-K
EX-99.1
PRFX
PainReform Ltd
15 Nov 23
Condensed Financial Statements
4:09pm
warrants were issued and classified as long term liability (Note 5e and 5f).
The accompanying notes are an integral part of the unaudited condensed … retroactively adjusted to reflect a 1-for-10 reverse share split (Note 5d).
(***) The warrants are classified as liability (Notes 5e, 5f)
F - 9
6-K/A
EX-99.1
7lrteq 6p
4 May 23
Annual General Meeting of Shareholders to Be
8:19am
6-K
EX-99.1
8lot9crsgirg
3 May 23
Annual General Meeting of Shareholders to Be
5:25pm
6-K
EX-99.2
ai1ljt pzgipu9gaw7z
15 Aug 22
Current report (foreign)
6:16pm
6-K
EX-99.3
8arc8 uasyzz5q96ltxf
13 May 21
PAINREFORM LTD. Condensed UNAUDITED FINANCIAL STATEMENTS
9:18am
20-F
m9t8ikj84rl9tmh4s39
18 Mar 21
Annual report (foreign)
9:03am
6-K
EX-99.1
kap6oaht2p
4 Jan 21
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
4:16pm
6-K
EX-99.1
j49qv2v70rlyta6kzs
19 Oct 20
PainReform Highlights Surgical Advantages of PRF-110
1:37pm
424B3
ejgglcm qnz
30 Sep 20
Prospectus supplement
4:42pm
6-K
EX-99.1
8hy4hv9 t4pj1
30 Sep 20
Condensed Financial Statements
4:32pm
6-K
EX-99.2
9wabn09f
30 Sep 20
Condensed Financial Statements
4:32pm
424B4
p40m vugmrp
2 Sep 20
Prospectus supplement with pricing info
4:09pm
F-1/A
x6yrxaxhe c9x
31 Aug 20
Registration statement (foreign) (amended)
6:06am
F-1/A
04285
24 Aug 20
Registration statement (foreign) (amended)
12:15pm
F-1/A
ccq7xzfykiu7
10 Aug 20
Registration statement (foreign) (amended)
4:15pm